Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Allogeneic CAR-NK Therapy Development Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The field of cancer immunotherapy has witnessed a paradigm shift with the advent of allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapies. These off-the-shelf therapeutic products offer a promising alternative to traditional autologous CAR-T therapies, addressing several limitations and extending the benefits of immunotherapy to a broader patient population. Creative Biolabs is dedicated to providing unparalleled Allogeneic CAR-NK development services to foster the next generation of immunotherapeutics.

The Potential of Allogeneic CAR-NK

• Overcoming Limitations of CAR-T Therapies

Autologous CAR-T cell therapies have revolutionized the treatment of hematological malignancies but are not without drawbacks. These treatments are costly, time-intensive, and often unavailable to patients with rapidly progressing conditions. CAR-T therapies also carry risks of severe side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

In contrast, allogeneic CAR-NK therapies eliminate many of these hurdles. NK cells naturally exhibit a reduced risk of graft-versus-host disease (GVHD), and engineered NK cells have demonstrated significantly lower rates of CRS and ICANS. The scalability and immediate availability of off-the-shelf NK cells make them an efficient and economically viable therapeutic option.

• Broad-Spectrum Tumor Recognition

NK cells possess innate anti-tumor properties and can target cancer cells through various mechanisms, potentially reducing the risk of antigen escape: a common issue with CAR-T therapies. With advancements in genetic engineering, NK cells can be modified using technologies like CRISPR/Cas9 and base editing to enhance their functionality, specificity, and persistence.

Allogeneic CAR-NK Therapy Development Service at Creative Biolabs

• Comprehensive Development Platform

Creative Biolabs offers a robust platform for the development of allogeneic CAR-NK therapies. Our services encompass every stage of development, from initial cell sourcing and genetic engineering to large-scale manufacturing and quality control. By leveraging our extensive expertise and state-of-the-art facilities, we are committed to delivering high-quality, effective services and related products.

• Key Features of Our Allogeneic CAR-NK Development Service
  
  • Rapid Production Cycles: Our streamlined processes facilitate the rapid generation of CAR-NK cells, addressing the urgent needs of patients with aggressive cancers.
  • Scalability: The ability to produce large quantities of NK cells from a single donor allows for the treatment of multiple patients, significantly reducing costs and enhancing accessibility.
  • Enhanced Efficacy and Safety: Through careful genetic modifications, we improve the cytotoxicity, persistence, and tumor-homing capabilities of NK cells, all while minimizing adverse side effects.

Fig.1 Autologous and allogeneic NK cell therapy solutions.¹

Featured Services

Frequently Asked Questions

Q1: What makes allogeneic CAR-NK cells more advantageous than autologous CAR-NK cells?

A2: Allogeneic CAR-NK cells are immediately available, highly scalable, economically feasible, exhibit lower toxicity, and can target tumors through multiple pathways, making them an attractive alternative.

Q2: What challenges exist in the development of allogeneic CAR-NK therapies?

A2: Key challenges include mitigating immune rejection and enhancing functional persistence and tumor-homing capabilities of NK cells. Creative Biolabs addresses these through advanced genetic engineering and optimized production processes.

Allogeneic CAR-NK therapy represents a groundbreaking advancement in cancer treatment, offering a viable, scalable, and efficacious alternative to existing therapies. By offering comprehensive and customizable services, Creative Biolabs empowers our clients to bring innovative cancer therapies from the bench to the bedside.

Reference

1. Quamine, Aicha E., et al. "Approaches to enhance natural killer cell-based immunotherapy for pediatric solid tumors." Cancers 13.11 (2021): 2796.